These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 20214748

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients.
    Demirjian S, Stephany B, Abu Romeh IS, Boumitri M, Yamani MH, Poggio ED.
    Clin Transplant; 2009; 23(3):351-60. PubMed ID: 19208105
    [Abstract] [Full Text] [Related]

  • 26. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [Abstract] [Full Text] [Related]

  • 27. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
    Balfour IC, Srun SW, Wood EG, Belsha CW, Marshall DL, Ferdman BR.
    J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
    [Abstract] [Full Text] [Related]

  • 28. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 29. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of sirolimus and everolimus in heart transplant patients: a retrospective analysis.
    Baur B, Oroszlan M, Hess O, Carrel T, Mohacsi P.
    Transplant Proc; 2011 Jun; 43(5):1853-61. PubMed ID: 21693289
    [Abstract] [Full Text] [Related]

  • 31. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients.
    Rogers CC, Johnson SR, Mandelbrot DA, Pavlakis M, Horwedel T, Karp SJ, Egbuna O, Rodrigue JR, Chudzinski RE, Goldfarb-Rumyantzev AS, Hanto DW, Curry MP.
    Clin Transplant; 2009 Jun; 23(6):887-96. PubMed ID: 19681971
    [Abstract] [Full Text] [Related]

  • 32. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation.
    Pescovitz MD, Nezakatgoo N, Lorber MI, Nashan B, Tedesco-Silva H, Kasiske BL, de la Cruz FJ, Russ G, Campistol J, Keown PA, International Sirolimus Study Group.
    Transplantation; 2009 Oct 27; 88(8):1010-8. PubMed ID: 19855247
    [Abstract] [Full Text] [Related]

  • 33. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.
    Liver Transpl; 2008 May 27; 14(5):651-9. PubMed ID: 18433069
    [Abstract] [Full Text] [Related]

  • 34. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2003 Jul 27; 76(2):364-70. PubMed ID: 12883194
    [Abstract] [Full Text] [Related]

  • 35. The natural history of renal function following orthotopic heart transplant.
    Al Aly Z, Abbas S, Moore E, Diallo O, Hauptman PJ, Bastani B.
    Clin Transplant; 2005 Oct 27; 19(5):683-9. PubMed ID: 16146562
    [Abstract] [Full Text] [Related]

  • 36. Sirolimus in chronic allograft nephropathy in pediatric recipients.
    Ibáñez JP, Monteverde ML, Diaz MA, Goldberg J, Turconi AF.
    Pediatr Transplant; 2007 Nov 27; 11(7):777-80. PubMed ID: 17910656
    [Abstract] [Full Text] [Related]

  • 37. Sirolimus in pediatric liver transplantation: a single-center experience.
    Gibelli NE, Tannuri U, Pinho-Apezzato ML, Tannuri AC, Maksoud-Filho JG, Andrade WC, Velhote MC, Santos MM, Ayoub AA, Marques da Silva M.
    Transplant Proc; 2009 Apr 27; 41(3):901-3. PubMed ID: 19376384
    [Abstract] [Full Text] [Related]

  • 38. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
    Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold HK, Koerfer R.
    Clin Transplant; 2007 Apr 27; 21(4):536-43. PubMed ID: 17645716
    [Abstract] [Full Text] [Related]

  • 39. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 40. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.
    Liver Transpl; 2007 Dec 15; 13(12):1694-702. PubMed ID: 18044728
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.